Company: CRNX
Filing Date: 2025-02-24
Form Type: 8-K
Source: 0000950170-25-025248
Chunk: 3

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-24
Form: 8-K
Item: Item 5.02
Chunk 3
---
 the Employment Agreement contained in this Item 5.02 is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which will be filed with the Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Departure of Mr. Wilson

As previously reported on the Current Report on Form 8-K filed by the Company on August 8, 2024, Marc Wilson notified the Company of his decision to step down from his position as Chief Financial Officer of the Company. His resignation will be effective February 28, 2025. Mr. Wilson is departing for personal reasons, not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Wilson will remain with the Company for a period of time to assist with the transition of his duties to Mr. Schilke and others within the Company and to ensure the continuity of its programs.

Item 7.01 Regulation FD Disclosure.